Cullinan Therapeutics doses first patient in Phase 2 CLN-049 AML study
Cullinan Therapeutics said its planned registrational Phase 2 study of CLN-049 in relapsed/refractory acute myeloid leukemia has dosed its first patient.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.